Review and critique of the Institute of Medicine report "the future of drug safety".
In September 2006 an Institute of Medicine (IOM) ad hoc committee on the Assessment of the US Drug Safety System released its report entitled "The Future of Drug Safety: Promoting and Protecting the Health of the Public". The committee's report includes 25 recommendations that "will bring the strengths of the preapproval process (data, regulatory authority, organizational function and capabilities, and resources) to the postapproval phase in order to fulfill a lifecycle approach to the study, regulation, and communication about the risks and benefits of drugs." Copies of the report are available from the National Academies Press (800-624-6242), and the full text is available at http://www.nap.edu.
Benet
L Z
LZ
Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California, USA. Leslie.Benet@ucsf.edu
D004341:Drug Evaluation; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control*; D005544:Forecasting; D006801:Humans; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D011634:Public Health / Q000592:standards / Q000639:trends; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards